RxDoctor Payments Data

Cristina Nunez-Christopher

Physician Assistant · New Hyde Park, NYNPI 1730215013

Payments from drug & device makers

$3,556in general payments, 2019–2025

Across 78 payments — averaging $45.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$493
  • Boston Scientific$416
  • AbbVie$385
  • Ardelyx, Inc.$227
  • Braintree Laboratories, Inc.$225
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$214
  • plus $2K from 14 others

What the payments were for

  • Food & beverage$3,556100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,556 in reported general payments places this provider in the 90th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$12,156
Medicare patients
100
Services billed
159

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab24$670,254
LinzessLinaclotide78$100,258
XifaxanRifaximin17$34,523
CreonLipase/Protease/Amylase13$32,893
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate11$27,230
PentasaMesalamine28$23,658
Mesalamine51$17,584
Pantoprazole Sodium729$13,578
MotegrityPrucalopride Succinate11$13,435
Dexlansoprazole DrDexlansoprazole35$11,841
SutabSod Sulf/Pot Chloride/Mag Sulf54$8,571
MovantikNaloxegol Oxalate13$6,567
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates63$3,950
Omeprazole183$2,774
Colestipol Hcl36$2,694

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$190$670,25424 claims
AbbVieLinzess, Creon$385$133,15191 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$214$34,52317 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$68$13,43511 claims
Braintree Laboratories, Inc.Sutab$225$8,57154 claims
Redhill Biopharma Inc.Movantik$157$6,56713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in New Hyde Park

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →